Uses
VYEPTI is indicated for the preventive treatment of migraine in adults. VYEPTI is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults
Source: US FDA prescribing information
Molecule
Eptinezumab
Calcitonin Gene-related Peptide Antagonist
- Presentations
- 1
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Eptinezumab is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults. It is available as injection for intravenous use. MedsAcross supplies Eptinezumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Calcitonin Gene-related Peptide Antagonist, Calcitonin Gene-related Peptide Antagonists
- ATC classification
- N02CD Antimigraine, subgroup N02CD · Antimigraine
- US FDA first approval
- 21 February 2020
- EU status
- Authorised
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Intravenous
- Dosage forms
- Injection
- Biologic
- Yes
- Identifiers
- UNII 8202AY8I7HCAS 1644539-04-7DrugBank DB14040Q28208949
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Source: US FDA prescribing information
Dosing overview
Must dilute before use. For intravenous infusion only. Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg every 3 months. Dilute only in 100 mL of 0.9% Sodium Chloride Injection
Source: US FDA prescribing information
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients in VYEPTI. Reactions have included anaphylaxis and angioedema. VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients
Source: US FDA prescribing information
Warnings and precautions
Hypersensitivity Reactions: If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and initiate appropriate therapy. Constipation with Serious Complications: Serious complications of constipation may occur. Hypertension: New-onset or worsening of pre-existing hypertension may occur. Raynaud’s Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur
Source: US FDA prescribing information
Side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions. Constipation with Serious Complications Hypertension Raynaud’s Phenomenon The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity
Source: US FDA prescribing information
Storage
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze or shake.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
1 presentations of Eptinezumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Vyepti 100 mg/1 mL injectionIntravenous Cold chain | Lundbeck Pharmaceuticals | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Questions and answers
Is Eptinezumab available for export from India?
Yes, on request. MedsAcross lists 1 presentations of Eptinezumab and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Eptinezumab have?
The catalogue lists 1 brand names for Eptinezumab, including Vyepti.
Is Eptinezumab approved by the US FDA?
Yes. The US FDA first approved Eptinezumab on 21 February 2020, according to Drugs@FDA.
Is Eptinezumab authorised in the European Union?
Yes. Eptinezumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Eptinezumab need cold chain shipping?
At least one listed presentation of Eptinezumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Which ATC class is Eptinezumab in?
Eptinezumab is classified under ATC code N02CD (Antimigraine, subgroup N02CD).
References
- Vyepti prescribing information (Lundbeck Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 5 June 2026
- Vyepti: European public assessment report (EPAR). European Medicines Agency. Retrieved 10 November 2026
Request Eptinezumab for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.